Literature DB >> 27718085

Hypogammaglobulinemia in infants receiving chronic peritoneal dialysis.

Shwetal Lalan1, Hongying Dai2, Bradley A Warady3.   

Abstract

BACKGROUND: Peritonitis is a severe complication of chronic peritoneal dialysis (CPD) in infants. Few studies have been conducted to evaluate the relationship between hypogammaglobulinemia and peritonitis risk, and the potential benefit of intravenous immunoglobulins (IVIG) therapy in infants receiving CPD.
METHODS: Patients aged 0-12 months at initiation of CPD between 1985 and 2012 were eligible for inclusion in this retrospective study. Data collected from the start of CPD up to 2 years post-dialysis initiation included patient demographics, dialysis characteristics, serum immunoglobulin (IgG) levels, IVIG administration history, infectious complications and outcomes. Cox regression analysis and linear mixed model analysis were used for statistical analysis.
RESULTS: Twenty-six consecutive patients were included in the study. Annualized peritonitis rates for infants aged 0-30 days (≤1-month age group; n = 16; 320.3 patient-months) and 31-365 days (>1-12-month age group; n = 10; 163.3 patient-months) at dialysis initiation were 0.27 (1 episode per 45.8 patient-months) and 0.15 (one episode per 81.7 patient-months), respectively. Seventy-six percent of the serum IgG levels were >1 standard deviation below the age-appropriate mean levels, and these did not differ in those who developed peritonitis versus those who did not (p = 0.39). Serum IgG levels were significantly lower in patients on CPD with oligoanuria than in non-oliguric patients (p = 0.04) and in patients on CPD for >90 days as compared to those who had received CPD for <90 days (p = 0.018). IVIG therapy was provided to 20 patients with hypogammaglobulinemia; this high prevalence of IVIG usage precluded any drawing of conclusion on the potential role of IVIG in the prevention of peritonitis.
CONCLUSIONS: Hypogammaglobulinemia is a frequent complication of CPD during infancy. In our experience, it was not associated with an increased risk for peritonitis.

Entities:  

Keywords:  Hypogammaglobulinemia; Immunoglobulin; Infant dialysis; Neonates; Peritoneal dialysis

Mesh:

Substances:

Year:  2016        PMID: 27718085     DOI: 10.1007/s00467-016-3487-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  20 in total

1.  Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis.

Authors:  B A Warady; F Schaefer; M Holloway; S Alexander; M Kandert; B Piraino; I Salusky; A Tranaeus; J Divino; M Honda; S Mujais; E Verrina
Journal:  Perit Dial Int       Date:  2000 Nov-Dec       Impact factor: 1.756

2.  Outcomes of dialysis initiated during the neonatal period for treatment of end-stage renal disease: a North American Pediatric Renal Trials and Collaborative Studies special analysis.

Authors:  William A Carey; Lynya I Talley; Sally A Sehring; Janet M Jaskula; Robert S Mathias
Journal:  Pediatrics       Date:  2007-01-15       Impact factor: 7.124

Review 3.  Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.

Authors:  Bradley A Warady; Sevcan Bakkaloglu; Jason Newland; Michelle Cantwell; Enrico Verrina; Alicia Neu; Vimal Chadha; Hui-Kim Yap; Franz Schaefer
Journal:  Perit Dial Int       Date:  2012-06       Impact factor: 1.756

4.  Effect of intraperitoneal immunoglobulin infusion on neutrophil function in CAPD children with and without peritonitis.

Authors:  S Akman; A G Güven; S Ince; O Yegin
Journal:  Adv Perit Dial       Date:  1998

5.  Peritonitis prevention in CAPD by intraperitoneal IgG.

Authors:  S Lamperi; S Carozzi
Journal:  Contrib Nephrol       Date:  1989       Impact factor: 1.580

6.  Hypogammaglobulinemia in infants and young children maintained on peritoneal dialysis. Pediatric Dialysis Study Consortium.

Authors:  A M Neu; B A Warady; H M Lederman; S L Furth; B A Fivush
Journal:  Perit Dial Int       Date:  1998 Jul-Aug       Impact factor: 1.756

7.  Response of CAPD patients with a high incidence of peritonitis to intraperitoneal immunoglobulin therapy.

Authors:  S Carozzi; M G Nasini; A Kunkl; S Cantarella; S Lamperi
Journal:  ASAIO Trans       Date:  1988 Jul-Sep

8.  Peritoneal dialysis in infants: the experience of the Italian Registry of Paediatric Chronic Dialysis.

Authors:  Enrico Vidal; Alberto Edefonti; Luisa Murer; Bruno Gianoglio; Silvio Maringhini; Carmine Pecoraro; Palma Sorino; Giovanna Leozappa; Giancarlo Lavoratti; Ilse Maria Ratsch; Roberto Chimenz; Enrico Verrina
Journal:  Nephrol Dial Transplant       Date:  2011-06-09       Impact factor: 5.992

9.  Risk Factors Associated with Nosocomial Peritonitis in Children on Peritoneal Dialysis.

Authors:  Desirée López-González; Juan Garduño; Alfonso Reyes-López; Armando Partida-Gaytán; Mara Medeiros
Journal:  Rev Invest Clin       Date:  2015 May-Jun       Impact factor: 1.451

10.  Clinical practice recommendations for the care of infants with stage 5 chronic kidney disease (CKD5).

Authors:  Aleksandra M Zurowska; Michel Fischbach; Alan R Watson; Alberto Edefonti; Constantinos J Stefanidis
Journal:  Pediatr Nephrol       Date:  2012-10-09       Impact factor: 3.714

View more
  3 in total

1.  Fungal peritonitis in the Standardizing Care to Improve Outcomes in Pediatric End Stage Renal Disease (SCOPE) Collaborative.

Authors:  Raj Munshi; Christine B Sethna; Troy Richardson; Jonathan Rodean; Samhar Al-Akash; Sushil Gupta; Alicia M Neu; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2018-01-08       Impact factor: 3.714

2.  Peritoneal dialysis and infants: further insights into a complicated relationship.

Authors:  Enrico Vidal
Journal:  Pediatr Nephrol       Date:  2017-12-07       Impact factor: 3.714

Review 3.  Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.

Authors:  Hans-Hartmut Peter; Hans D Ochs; Charlotte Cunningham-Rundles; Donald C Vinh; Peter Kiessling; Bernhard Greve; Stephen Jolles
Journal:  J Allergy Clin Immunol       Date:  2020-09       Impact factor: 10.793

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.